Abeona Therapeutics (ABEO) EBITDA Margin (2011 - 2026)

Abeona Therapeutics' EBITDA Margin history runs 13 years deep, the most recent figure standing at 264.14% for Q1 2026.

• In Q1 2026, EBITDA Margin changed N/A year-over-year to 264.14%; the TTM figure through Mar 2026 stood at 637.92% (changed N/A YoY), while the FY2025 annual figure was 1536.91%, changed N/A from the prior year.
• EBITDA Margin for Q1 2026 stood at 264.14%, up from 422.71% in the prior quarter.
• The five-year high for EBITDA Margin was 264.14% in Q1 2026, with the low at 19023.53% in Q4 2022.
• The 4-year median for EBITDA Margin is 800.8% (2022), against an average of 4637.41%.
• Peak annual rise in EBITDA Margin reached 49926 bps in 2023, while the deepest fall reached 49926 bps in 2023.
• Abeona Therapeutics' EBITDA Margin stood at 19023.53% in 2022, then surged by 98 bps to 301.54% in 2023, then slumped by 40 bps to 422.71% in 2025, then soared by 38 bps to 264.14% in 2026.
• Business Quant data shows ABEO's EBITDA Margin at 264.14% in Q1 2026, 422.71% in Q4 2025, and 5698.0% in Q2 2025.